MACSF

COMMUNIQUÉS West-GlobeNewswire

Safest SARMs For Muscle Growth 2025: CrazyBulk Introduces Effective SARMs For Bulking, Cutting and Strength in USA.
15/07/2025
Albany, New York, July 15, 2025 (GLOBE NEWSWIRE) -- In the ever-evolving world of fitness and bodybuilding, achieving optimal muscle growth, fat loss, and recovery without compromising health is paramount. Selective [...]
Aurora Spine Announces Participation in 7th Annual American Society of Pain & Neuroscience Conference
15/07/2025
CARLSBAD, California, July 15, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in innovative spine and interventional pain management solutions, [...]
Neuronetics Appoints New Chief Financial Officer
15/07/2025
Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Steve Furlong as Chief Financial Officer following previously announced succession process [...]
Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases
15/07/2025
Presentation by trial principal investigator at the 2025 SNO/ASCO CNS Metastases Conference Plus will also host an educational symposium with leading experts titled, “Reimagining Your Approach to Leptomeningeal [...]
ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
15/07/2025
FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetes FDA also confirmed that the ongoing Phase 3 PROACT 1 study can be used [...]
BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer
15/07/2025
PHILADELPHIA and VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company [...]
ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area
15/07/2025
- Lucile Packard Children’s Hospital Stanford is ready to accept patients for ZEVASKYN treatment - - Abeona Therapeutics ® and Stanford Medicine conducted research collaboration for more than a decade, culminating in U. [...]
Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025
15/07/2025
GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, August 6, 2025, at 5:00 pm eastern time to discuss the financial results for the [...]
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
15/07/2025
SAN CARLOS, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor [...]
Hengrui Pharma and Kailera Therapeutics Report Positive Topline Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531
15/07/2025
– Mean weight loss of 19.2% at 6 mg with no plateau in 48-week Phase 3 trial – – Favorable safety profile consistent with other GLP-1-based treatments – – Hengrui to submit NDA in China; Kailera plans to evaluate both [...]
SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study
15/07/2025
The Trial Exceeded Target Overall Response Rate (ORR) of 20%, with 44% Response Rate Among Patients with Acute Myeloid Leukemia-Myelodysplasia-Related Changes (AML MR) Treated at Optimal Dose of 30 mg Twice a Week (BIW [...]
Polyrizon Retains Nasdaq Listing Following Hearings Panel
15/07/2025
Raanana, Israel, July 15, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, [...]
PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market
15/07/2025
PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP-1 for approximately 60 days, compared to current standard of care of weekly injections. The [...]
Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01
15/07/2025
Dr. Lotan’s distinguished expertise in bladder cancer care and clinical development brings further scientific acumen to Relmada’s NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., [...]
Medera and University of Kansas Medical Center Announce First Patient Treated in Pioneering Gene Therapy Trial for Duchenne Muscular Dystrophy Associated Cardiomyopathy
15/07/2025
Landmark MUSIC-DMD Phase 1b trial represents first-in-human gene therapy approach for DMD-associated heart failure BOSTON and KANSAS CITY, Kan., July 15, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage [...]
HealthLynked Engages Meridian Group to Accelerate Strategic Partnerships and Revenue Growth
15/07/2025
NAPLES, Fla., July 15, 2025 (GLOBE NEWSWIRE) -- via IBN – HealthLynked Corp. ( OTCQB: HLYK ), a leader in healthcare technology and patient engagement solutions, today announced that it has engaged Meridian Group, a [...]
Extendicare Announces July 2025 Dividend of C$0.042 per Share
15/07/2025
MARKHAM, Ontario, July 15, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company for the month of [...]
OncoC4 to Present at the 2025 Orphan Drug Summit on Strategies to Eliminate Anti-Drug Antibodies in Orphan Therapies
15/07/2025
Multipronged approach to overcome the challenge of anti-drug antibodies to serve as the foundation of new subsidiary, AdaMunix ROCKVILLE, Md., July 15, 2025 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late-stage [...]
Nautilus Biotechnology to Announce Second Quarter 2025 Financial Results on July 31, 2025
15/07/2025
SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it [...]

Pages